These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 11357233)

  • 1. Evidence-based medicine in botulinum toxin therapy for cervical dystonia.
    Ceballos-Baumann AO
    J Neurol; 2001 Apr; 248 Suppl 1():14-20. PubMed ID: 11357233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A].
    Cardoso F
    Arq Neuropsiquiatr; 2003 Sep; 61(3A):607-10. PubMed ID: 14513166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label study of botulinum toxin A for treatment of tardive dystonia.
    Tarsy D; Kaufman D; Sethi KD; Rivner MH; Molho E; Factor S
    Clin Neuropharmacol; 1997 Feb; 20(1):90-3. PubMed ID: 9037579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with botulinum toxin injections does not change brainstem interneuronal excitability in patients with cervical dystonia.
    Valls-Sole J; Tolosa ES; Marti MJ; Allam N
    Clin Neuropharmacol; 1994 Jun; 17(3):229-35. PubMed ID: 9316668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
    Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Moore D
    J Cosmet Laser Ther; 2002 Mar; 4(1):15-8. PubMed ID: 12079632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study.
    Laubis-Herrmann U; Fries K; Topka H
    Eur Neurol; 2002; 47(4):214-21. PubMed ID: 12037435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of cervical dystonia with botulinum toxin in a patient with myasthenia gravis.
    Gonçalves MR; Barbosa ER; Zambon AA; Marchiori PE
    Arq Neuropsiquiatr; 1999 Sep; 57(3A):683-5. PubMed ID: 10667297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study.
    Wissel J; Kanovsky P; Ruzicka E; Bares M; Hortova H; Streitova H; Jech R; Roth J; Brenneis C; Müller J; Schnider P; Auff E; Richardson A; Poewe W
    J Neurol; 2001 Dec; 248(12):1073-8. PubMed ID: 12013585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific characteristics of the medical history of swallowing before and after application of botulinum toxin in patients with cervical dystonia.
    Vilanova TFDD; Borges V; Ferraz HB
    Clinics (Sao Paulo); 2019 Apr; 74():e776. PubMed ID: 30942281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Botulinum A toxin in the treatment of focal dystonias].
    Domzał TM
    Neurol Neurochir Pol; 1998; 32 Suppl 1():35-44. PubMed ID: 9608551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
    Costa J; Borges A; Espírito-Santo C; Ferreira J; Coelho M; Moore P; Sampaio C
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004314. PubMed ID: 15674940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The botulinum toxins in the treatment of cervical dystonia.
    Brashear A
    Semin Neurol; 2001; 21(1):85-90. PubMed ID: 11346029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Jaw-opening oromandibular dystonia secondary to Wilson's disease treated with botulinum toxin type A.
    Teive HA; Klüppel LE; Munhoz RP; Becker N; Müller PR; Werneck LC
    Arq Neuropsiquiatr; 2012 Jun; 70(6):407-9. PubMed ID: 22699536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A.
    Brashear A; Ambrosius WT; Eckert GJ; Siemers ER
    Mov Disord; 1998 Jan; 13(1):158-61. PubMed ID: 9452343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials.
    Lew MF; Brashear A; Factor S
    Neurology; 2000; 55(12 Suppl 5):S29-35. PubMed ID: 11188982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin A for patients with orofacial dystonia: prospective, observational, single-centre study.
    Ruiz-de-León-Hernández G; Díaz-Sánchez RM; Torres-Lagares D; Hernández-Pacheco E; González-Martín M; Serrera-Figallo MA
    Int J Oral Maxillofac Surg; 2018 Mar; 47(3):386-391. PubMed ID: 29208327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based medicine: botulinum toxin in focal hyperhidrosis.
    Naumann M
    J Neurol; 2001 Apr; 248 Suppl 1():31-3. PubMed ID: 11357238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of botulinum toxin the the treatment of muscle pain].
    Benecke R; Dressler D; Kunesch E; Probst T
    Schmerz; 2003 Dec; 17(6):450-8. PubMed ID: 14648320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia.
    Ansved T; Odergren T; Borg K
    Neurology; 1997 May; 48(5):1440-2. PubMed ID: 9153487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incobotulinum toxin A in Parkinson's disease with foot dystonia: A double blind randomized trial.
    Rieu I; Degos B; Castelnovo G; Vial C; Durand E; Pereira B; Simonetta-Moreau M; Sangla S; Fluchère F; Guehl D; Burbaud P; Geny C; Gayraud D; Ory-Magne F; Bouhour F; Llinares E; Derost P; Marques A; Durif F
    Parkinsonism Relat Disord; 2018 Jan; 46():9-15. PubMed ID: 29102441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.